ARTICLE | Clinical News

Jardiance empagliflozin regulatory update

January 26, 2015 8:00 AM UTC

NICE issued draft guidance recommending Jardiance empagliflozin from Boehringer Ingelheim to treat Type II diabetes. Boehringer provided a new cost-effectiveness model demonstrating that the product is cost effective when compared to recommended treatments, as requested in earlier draft guidance from NICE (see BioCentury, Sept.1, 2014). Specifically, Jardiance is recommended in a dual therapy regimen in combination with metformin only if a sulfonylurea is contraindicated or not tolerated or the patient is at significant risk of hypoglycemia or its consequences; in a triple therapy regimen with metformin and a sulfonylurea or metformin and a thiazolidinedione; and in combination with insulin with or without other antidiabetic drugs. ...